Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes

A method for treating a patient suffering from a metabolic disorder, comprising the step of administering to a patient in need of such treatment a dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic that increases the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system or within the hypothalamus of the central nervous system of said patient.

A method for treating a patient suffering from a metabolic disorder, comprising the step of:

• administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in said subject, and (2) at least one compound that stimulates a decrease in central noradrenergic and/or serotonin neuronal activity level in said subject.

A method of treating at least one non-metabolic derangement in a patient, comprising the step of administering to a patient suffering from said non-metabolic derangement a therapeutically effective amount of a dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic, said dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic effective to treat said at least one non-metabolic derangement in said patient.

A method of treating at least one metabolic derangement and at least one non-metabolic derangement in a patient, comprising the step of administering to a patient suffering from said metabolic derangement and said non-metabolic derangement a therapeutically effective amount of a dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic, said a dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic effective to treat said at least one metabolic derangement and said at least one non-metabolic derangement in said patient.

A method of treating at least one vascular disease in a patient, comprising the step of administering to a patient suffering from said at least one vascular disease a therapeutically effective amount of a dopamine/norepinephrine and/or serotonin neuronal activity ratio-increasing therapeutic, said dopamine/norepinephrine neuronal activity ratio-increasing therapeutic effective to treat said at least one vascular disease in said patient.

A pharmaceutical composition effective for treating the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, said composition comprising

• at least one compound that simultaneously stimulates (1) an increase in central dopaminergic neuronal activity level, and (2) a decrease in central noradrenergic and/or serotonin neuronal activity level, said compound selected from the group consisting of catecholamine modifiers and
• a pharmaceutically acceptable carrier.